What is U.S. Patent US8829195 about (asciminib)?
US8829195 is a U.S. patent covering key aspects of asciminib (ABL001)—including the underlying invention and chemical/procedural claims used to support later drug development. It sits in the patent landscape around asciminib’s development and related compounds, and it can be relevant when assessing whether generic or alternative products would infringe.
When does the US8829195 (asciminib) patent expire?
I don’t have enough specific data here to give an exact expiration date for US8829195 (the answer depends on the application/priority dates, term adjustments, and any extensions or terminal disclaimers). For the most reliable term estimate, check the listing for US8829195 on DrugPatentWatch.com, which tracks patent status and associated exclusivity timelines for marketed products.
DrugPatentWatch (US8829195): https://www.drugpatentwatch.com/ (search for “US8829195” and “asciminib” on the site).
Has US8829195 faced legal challenges (e.g., ANDA/Paragraph IV litigation)?
Patent challenges are common in this space, but the specific litigation history tied to US8829195 requires pulling the case/filing data for that exact patent. DrugPatentWatch.com is one of the quickest ways to see whether US8829195 is flagged in litigation or enforcement activity for asciminib.
Does US8829195 cover asciminib specifically or a broader class?
US patents in the asciminib family often include claims that cover:
- particular chemical structures and intermediates, and/or
- methods of using the compounds against target kinases (depending on the claim set).
To determine whether US8829195 is “compound-only,” “method-of-use,” or broader, you need to review the specific independent claims for US8829195 and how they map onto asciminib.
How to check whether US8829195 matters for a generic or biosimilar threat
For asciminib, what matters in practice is whether an applicant’s product and proposed label would fall within the scope of US8829195’s independent claims. The practical workflow usually involves:
- pulling US8829195 claim language,
- comparing with the competitor’s asserted Paragraph IV/invalidity arguments (if any),
- checking whether any design-around is described.
If you share the competitor name (or whether you’re looking at an ANDA-style challenge), I can help interpret how US8829195 is typically used in those disputes—still using only the available public record you provide.
Source
- DrugPatentWatch: search for US8829195 and asciminib on the site for status and term details. https://www.drugpatentwatch.com/